Clinical trial NCT00093704 (phase 1, status: terminated)
Conditions: lymphoma, lymphoproliferative disorder
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D47.Z1
Drugs: bortezomib + ganciclovir
SMILES: NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Reason stopped: 
    study could not recruit any more patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed Epstein Barr virus-positive lymphoma, including the following
             subtypes:

               -  Post-transplantation lymphoma

               -  Burkitt's lymphoma

               -  Hodgkin's lymphoma

               -  T-/NK-cell lymphoma

          -  Unresponsive to, or relapsed after, at least 1 prior chemotherapy regimen

          -  Bidimensionally measurable disease by CT scan

          -  At least 1 lesion ≥ 1.5 cm in the greatest diameter

          -  Age 18 and over

          -  ECOG 0-2 OR

          -  Karnofsky 50-100%

          -  Life expectancy More than 3 months

          -  Hematopoietic

               -  Absolute neutrophil count ≥ 1,000/mm^3 (no growth factor support within the past
                  4 weeks)

               -  Hemoglobin ≥ 9.0 g/dL

               -  Platelet count ≥ 50,000/mm^3 (no platelet transfusions within the past 4 weeks)

          -  Hepatic

               -  Bilirubin ≤ 2.0 times upper limit of normal (ULN)

               -  AST and ALT ≤ 2.5 times ULN (5 times ULN in patients with liver involvement)

               -  No active hepatitis B or C

          -  Renal

               -  Creatinine clearance ≥ 60 mL/min

               -  Sodium > 130 mmol/L

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  At least 4 weeks since prior immunotherapy

          -  At least 4 weeks since prior chemotherapy

          -  At least 4 weeks since prior radiotherapy

          -  More than 4 weeks since prior major surgery unless fully recovered

          -  Recovered from all prior therapy

          -  At least 4 weeks since prior investigational agents

        Exclusion Criteria:

          -  primary or secondary CNS lymphoma or HIV-related lymphoma

          -  known brain metastases

          -  myocardial infarction within the past 6 months

          -  acute ischemia or new conduction system abnormalities by electrocardiogram

          -  symptomatic congestive heart failure

          -  unstable angina pectoris

          -  cardiac arrhythmia

          -  hospitalized

          -  pregnant or nursing

          -  other uncontrolled illness

          -  ongoing or active systemic infection

          -  psychiatric illness or social situation that would preclude study compliance

          -  history of allergic reaction attributable to compounds of similar chemical or
             biological composition to study drugs

          -  sensitivity to boron, mannitol, bortezomib, or ganciclovir

          -  concurrent corticosteroids (≥ 10 mg of prednisone or equivalent)

          -  concurrent radiotherapy

          -  other concurrent anticancer therapy

          -  other concurrent investigational agents